Effects of dapaglifloziN Therapy on Myocardial Perfusion Reserve in Prediabetic Patients With Stable coronarY Artery Disease

Sponsor
CHEOL WHAN LEE, M.D., Ph.D
Study ID
NCT04330079
Phase
PHASE4
Status
Terminated

Conditions

  • Coronary Artery Disease
  • Prediabetic State

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin 10mg — DRUG
    Dapagliflozin 10mg once daily for 6 months.
  • Lifestyle modification — OTHER
    lifestyle modification (diet and exercise) for 6 months

Study Details

The purpose of this study is to investigate the effects of dapagliflozin therapy on myocardial perfusion reserve (MPR) using dynamic SPECT examination in prediabetic patients with stable CAD. Dapagliflozin therapy versus lifestyle modification improves myocardial perfusion reserve in prediabetic patients with stable CAD.

Key Dates

Start date
May 21, 2020
Status verified
Sep 2022
Primary completion
Apr 8, 2021
Completion
Apr 8, 2021

Study Design

Enrollment
2 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Dapagliflozin
  • Other: Lifestyle modification

Primary Outcome Measure

Percent change in global myocardial perfusion reserve (MPR) index [ Time Frame: 6months ]

Related Studies